- Home
- EQX vs MDGL Comparison
EQX vs MDGL Comparison
Compare EQX & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQX | MDGL |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 12.1B |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | EQX | MDGL |
|---|---|---|
| Price | $13.98 | $520.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $17.00 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 8.8M | 355.7K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $102.84 | $58.39 |
| Revenue Next Year | $15.55 | $48.55 |
| P/E Ratio | $137.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.64 | $265.00 |
| 52 Week High | $18.96 | $615.00 |
Technical Indicators
Market Signals| Indicator | EQX | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 44.49 | 56.39 |
| Support Level | $13.54 | $503.93 |
| Resistance Level | $15.06 | $539.17 |
| Average True Range (ATR) | 0.62 | 16.69 |
| MACD | -0.02 | -1.95 |
| Stochastic Oscillator | 13.45 | 38.54 |
Price Performance
Historical ComparisonAbout EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.